Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good to know I could have done that.
Paper on what being added to the Russell Indices does as an investment strategy:
http://itg.com/news_events/papers/Investing_Russell.pdf
Several observations are in order. First, portfolios of actual index stock additions exhibit a monotonic decline in return as they are formed later in time. For instance, portfolios formed at the beginning of April yield over 12% average cumulative return until the effective date, while portfolios formed closer to mid-May yield only approximately 4%. This is intuitive, as knowing the new index composition earlier allows for more return opportunities due to
stocks’ fundamentals and to the excess demand from indexers. The situation changes dramatically once we consider portfolios of
projected index additions ... The returns do not depend much on the portfolio formation time and are actually slightly rising as portfolio gets formed later in time (from approximately 2.5% for portfolios formed 7-8 weeks prior to effective date to approximately 3% for portfolios formed 3-4 weeks prior to that date). A possible explanation is the interaction of two opposing effects.
As the holding period increases we can capture additional excess return; however, with the earlier formation date the quality of index projections also goes down. ...
Accounting for transaction costs results in a further decline in the returns on the portfolios of projected Russell 2000 stock additions. After accounting for costs, the strategy of buying the projected Russell additions yields average returns that range between 1.3% and 2.5% over the period of 2 to 3 months prior to the effective date. Again, the trend of rising returns for portfolios formed closer to effective date is visible (from 1.3% for the portfolios that were formed in early April to 2.5% for portfolios with formation date in mid May)
Apollo, Here is the site. Have not found her stuff yet myself.
http://annualmeeting.mscare.org/
Yup. Time to perhaps begin another leg up in pps.
Welcome over here too!
Opko Health Submits New Drug Application to FDA For Secondary Hyperparathyroidism
BY Midnight Trader
— 2:54 PM ET 05/29/2015
02:54 PM EDT, 05/29/2015 (MT Newswires) -- Opko Health ( OPK
Loading... Loading...
) said it has submitted a new drug application to the U.S. Food and Drug Administration for its Rayaldee drug to prevent and treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency.
"We believe Rayaldee will be the first product to receive FDA approval for this important indication," CEO Philip Frost said in a statement.
The application is based on positive data form three studies that met all primary efficacy and safety endpoints.
OPKO was lower 0.5% on Friday, near the top end of the 52-week range between $8.02 and $18.29.
Price: 17.64, Change: -0.10, Percent Change: -0.56
Agreed, Traffic is light. I guess people are waiting for news of one sort or other.
CHM, FWIW, there were some high volume days back in 11/2014 per stockhouse.
Miles, Fidelity is showing the price history correctly. Have no clue if I could trade them or not, since I have no interest in selling.
George,
PBTH was Prolor Biotech, which was acquired by OPK a while back. It provided the long-acting protein which powers human growth hormone (out-licensed now) and hemophilia drugs.
Steve
Is Casker's sold out as well? If there isn't much difference in price....
You did ask your friends if they would hold one for you, if it comes in again, right? BTW, was it the Groth aged Jeff's you were trying for?
Item was not readable.
Ahhh, the chance of a lifetime....lost.
Seriously, I can't imagine that as the last new product coming out. You may still find it somewhere else.
They are very much under the radar and don't telegraph their news.
Anyone notice the new ATM for $30mm i new shares?
Offer of Jeff's Groth Reserve at Caskers.
Jefferson's Reserve Groth Reserve Cask Finish Very Old Straight Bourbon Whiskey
This limited release was extra-matured in ex-Cabernet Sauvignon barrels from Napa Valley’s Groth Vineyards for nine months.
[was] $109.99 [now] $94.99
Jefferson's The Manhattan Barrel Finished Cocktail
This barrel-finished cocktail contains six-year-old Jefferson’s Bourbon and was created in partnership with Esquire's Editor-in-Chief, David Granger.
[was] $55.99 [now] $49.99
$oldier, My guess, given how Frost likes to roll up his businesses together into single/larger units and we have a Vector officer running ROX, is that Vector will be the acquirer for a fair but not fantastic premium over where ROX is trading at the time.
So good luck for all of us longs!
Good question about the volume. Stock price held up pretty well, so I assume there was a willing buyer. I saw no news.
Welcome aboard!
I'll take my ten bagger in the 2 stocks. Thank you very much.
Miles, A subway series means they BOTH have to win their respective leagues. I think NNAB and certain other stocks we have in common (Ultimate has only a limited list!) will win the home run contest before that.
Perhaps the great power you have as Mod can change this almost immutable fact. If that happens, I'll pull up a chair and watch.
G'nite guys.
MilesTeg Wednesday, 05/20/15 02:36:06 PM
Re: someconcerns post# 191
Post # of 192
Nope. Ultimate had it right.
Go Cubs!
I fear our calling it out may jinx it though.
I wish I had had the funds then to add more OPK at $8
And here is to the next Chai (double Chai) in OPK.
For those of you who may not know, Chai in Hebrew letters equals 18 and means "life" and has mystical significance. Gingi clearly knows.
This is true, but better accomplished in a Roth or IRA, rather than a taxable account. Hence my just staying long and riding the waves. Head still above water - well above my average sub $5 cost per share.
Ahem, go C**X, NNAB and white sox.
I'm more optimistic on the other company we both own and love.
NNAB will blossom before there is a subway series in Chicago. Forecasting either makes one seem a dreamer.
OK. Thanks.
Not a bad forecast. And tomorrow?
I agree. Not planning on selling my shares until Dr. Frost does likewise.
L'Chaim! OPK is now my largest holding. Just sitting, watching, waiting.
To tell you the truth, I enjoy reserve as much as presidential.
OK, thanks. Would not surprise me after the strength shown today.
In after hours trading. Nice that it didn't tank.
What is your expectation for the shares movement and how are you playing it?
It would be nice if it also went up 24% tuesday, but that was the percentage increase today - Monday.
So is the drug standard Lovastatin? If so, and if the dosage is within accepted Lovastatin human dosing, can we go directly to Ph 2? Or do we need a small POC study in humans?
I guess it would require changing your statin if you are already on one.
In my family, I haven't noticed their statin drugs reducing passing gas.
up 24 percent today
Tomorrow:
OraSure Technologies, Inc. (Nasdaq: OSUR) to Ring The Nasdaq Stock Market Opening Bell
Print
Alert
Orasure Technologies, Inc. (MM) (NASDAQ:OSUR)
Intraday Stock Chart
Today : Monday 18 May 2015
Click Here for more Orasure Technologies, Inc. (MM) Charts.
What:
OraSure Technologies, Inc. (Nasdaq:OSUR), a leader in point of care diagnostic tests and specimen collection devices, will visit the Nasdaq MarketSite in Times Square, in honor of National Hepatitis Testing Day.
OraSure Technologies’ OraQuick® HCV Rapid Antibody Test is the only FDA approved rapid hepatitis C test in the U.S. It is used in the U.S. and around the world to diagnose people at risk for hepatitis C, a disease that affects over 5.2 million people and infects 17,000 new people each year here in the U.S. It is estimated that up to 75 percent of those individuals infected with hepatitis C are unaware of their status.
In honor of the occasion, Douglas A. Michels, President and CEO of OraSure, will ring the Opening Bell. He will be joined by Dr. Marcelo Kugelmas, Gastroenterologist at South Denver Gastroenterology and member of the Chronic Liver Disease Foundation (CLDF) Board of Advisors.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Tuesday, May 19, 2015 – 9:15 a.m. to 9:30 a.m. ET
OraSure Technologies, Inc. Media Contact:
Jennifer Moritz
(917) 748-4006
jmoritz@0to5.com